10 December 2024NewsAmericasMuireann Bolger

‘AI curious’ counsel at AZ, Novartis weigh risks and benefits

Corporate legal teams can embrace the AI revolution by encouraging experimentation and managing risks proactively, according to a recent panel featuring leading pharma counsel.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
22 October 2024   Columbia court backs FDA approval of Entresto generic I Novartis appealing August ruling in Delaware that denied injunction.
Big Pharma
13 August 2024   Delaware judge denies pharma giant’s request for injunction on rivals’ generic of Entresto | Novartis ‘unlikely to succeed’ in proving infringement | Lawsuit is one of several attempts to preserve exclusivity of the drug ahead of patent expiry and US price caps.
Americas
5 September 2024   AstraZeneca unit and Samsung Bioepis resolve their patent dispute over a biosimilar | Settlement follows FDA approval for the generic drug in July 2024 | Agreement dismisses ongoing litigation and appeals, including a federal lawsuit and related patent reviews.

More on this story

Americas
22 October 2024   Columbia court backs FDA approval of Entresto generic I Novartis appealing August ruling in Delaware that denied injunction.
Big Pharma
13 August 2024   Delaware judge denies pharma giant’s request for injunction on rivals’ generic of Entresto | Novartis ‘unlikely to succeed’ in proving infringement | Lawsuit is one of several attempts to preserve exclusivity of the drug ahead of patent expiry and US price caps.
Americas
5 September 2024   AstraZeneca unit and Samsung Bioepis resolve their patent dispute over a biosimilar | Settlement follows FDA approval for the generic drug in July 2024 | Agreement dismisses ongoing litigation and appeals, including a federal lawsuit and related patent reviews.

More on this story

Americas
22 October 2024   Columbia court backs FDA approval of Entresto generic I Novartis appealing August ruling in Delaware that denied injunction.
Big Pharma
13 August 2024   Delaware judge denies pharma giant’s request for injunction on rivals’ generic of Entresto | Novartis ‘unlikely to succeed’ in proving infringement | Lawsuit is one of several attempts to preserve exclusivity of the drug ahead of patent expiry and US price caps.
Americas
5 September 2024   AstraZeneca unit and Samsung Bioepis resolve their patent dispute over a biosimilar | Settlement follows FDA approval for the generic drug in July 2024 | Agreement dismisses ongoing litigation and appeals, including a federal lawsuit and related patent reviews.